Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences, Inc., headquartered in Menlo Park, California, is a prominent medical device company dedicated to innovating and commercializing cutting-edge technologies for the treatment of prevalent eye diseases. The company operates through two main segments: Surgical Glaucoma and Dry Eye.
In the Surgical Glaucoma segment, Sight Sciences offers the OMNI Surgical System. This versatile device allows for both canaloplasty and trabeculotomy with a single corneal incision, aimed at reducing intraocular pressure in adults with primary open-angle glaucoma. The efficacy of OMNI has been demonstrated in multiple clinical trials, showing favorable outcomes in lowering intraocular pressure across various stages of glaucoma.
In the Dry Eye segment, the TearCare System is available for ophthalmologists and optometrists. This system helps manage dry eye disease through a single interventional eyelid procedure, providing significant improvements in the signs and symptoms of the condition over time.
Recent clinical trials have highlighted the effectiveness of these devices. For example, the GEMINI Study demonstrated successful results using OMNI combined with cataract surgery, and the SAHARA trial confirmed the benefits of TearCare compared to traditional treatments.
Financially, Sight Sciences derives key revenue from its Surgical Glaucoma segment. The company has seen active customer engagement, as evidenced by the number of OMNI and SION system orders, as well as TearCare SmartLids sales.
For investors and stakeholders, Sight Sciences continues to be a compelling entity with its relentless focus on reimagining eye care through transformative technologies. The company's commitment to improving patient outcomes and expanding its market presence underscores its significance in the ophthalmic medical device industry.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced the completion of enrollment in the SAHARA Trial, evaluating the effectiveness of the TearCare® device versus Restasis® eyedrops for chronic dry eye disease. This 310-patient randomized controlled trial aims to assess the superiority of the TearCare procedure in alleviating symptoms and improving eye surface conditions. Six-month efficacy results are expected by Summer 2023, with significant implications for treatment practices in dry eye disease anticipated from the outcome. The trial emphasizes a comprehensive approach to eye care.
Sight Sciences, an eyecare technology company listed on Nasdaq under the symbol SGHT, has announced its participation in the Morgan Stanley Global Healthcare Conference in New York City. The management will engage in a fireside chat scheduled for September 13, 2022, at 7:20 AM ET. Investors can access a live and archived webcast of the discussion through the 'Investors' section of their website. The company focuses on innovative solutions to improve patient care for eye diseases, including its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease.
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 2:30 PM ET. The event will be held virtually, and interested parties can access a live webcast through the provided link. An archived version will be available on the company's website post-event. Sight Sciences focuses on developing minimally invasive solutions for prevalent eye diseases, including the OMNI Surgical System and TearCare System, aimed at improving patient care.
Sight Sciences has launched SION, a new surgical instrument designed for goniotomy procedures, enhancing patient care in ophthalmic surgeries. SION's bladeless technology allows for smooth tissue removal by grasping diseased tissue without cutting, improving safety and ease of use. Developed with leading surgeons, the instrument is aimed at addressing the growing goniotomy market. CEO Paul Badawi emphasized SION's role in expanding Sight Sciences’ portfolio of minimally invasive solutions, furthering their commitment to innovation in treating prevalent eye diseases.
Sight Sciences (Nasdaq: SGHT) released three-year follow-up data showing the effectiveness of the OMNI Surgical System in treating open-angle glaucoma. The study revealed a mean reduction in intraocular pressure (IOP) of over 20% for all 26 patients, with IOP decreasing from 24.6 mmHg preoperatively to 15.0 mmHg at 36 months. Additionally, the mean number of IOP-lowering medications dropped significantly. Adverse events were minimal and resolved without intervention in most cases. This data underscores the long-term safety and efficacy of the OMNI system as a standalone treatment.
Sight Sciences, Inc. (Nasdaq: SGHT) reported robust financial results for Q2 2022, achieving total revenue of $17.2 million, a 37% increase from the previous year. The company expanded its gross margin to 84% and reported a 33% rise in Surgical Glaucoma revenue, totaling $15.9 million. Operating expenses rose to $37.4 million, significantly impacting net loss, which grew to $23.8 million ($0.50 per share). Looking ahead, Sight Sciences projects 2022 revenue between $68 million and $72 million, marking an anticipated growth of 39% to 47% compared to 2021.
Sight Sciences (Nasdaq: SGHT) will release its Q2 2022 financial results on August 11, 2022, after market close. A conference call discussing the results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors are encouraged to register for the audio webcast and will have access to a replay via the investor relations website. The company specializes in eyecare technology, aiming to improve care for prevalent eye diseases with innovative, minimally invasive solutions.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced the appointment of Tamara Fountain, M.D., to its Board of Directors, effective July 15, 2022. Dr. Fountain brings extensive ophthalmic experience, having served as President of the American Academy of Ophthalmology in 2021 and currently on the Board of the American Board of Ophthalmology. Her expertise is expected to enhance Sight Sciences' efforts in glaucoma and ocular surface disease, fostering partnerships within the ophthalmic community. The company continues to focus on innovative solutions for eye care, including its OMNI® Surgical System and TearCare® System.
Sight Sciences, Inc. (SGHT) announced positive results from the GEMINI study, demonstrating that its OMNI Surgical System effectively reduces unmedicated diurnal intraocular pressure (IOP) in open-angle glaucoma patients when combined with cataract surgery. The study revealed a mean IOP reduction of 35% at 12 months, with 84.2% of eyes achieving over 20% reduction. Notably, in a Hispanic subset, IOP decreased from 22.8 mmHg to 14.9 mmHg, with 87% requiring no medications. These findings underscore the significance of the OMNI system in glaucoma treatment, especially for demographics at higher risk.
Sight Sciences, Inc. (Nasdaq: SGHT) has announced its participation in the Piper Sandler Virtual Ophthalmology & Diabetes Symposium scheduled for May 23, 2022, at 10:00 AM PT. This event will feature a fireside chat with the company's management, accessible via webcast on their investor website. Sight Sciences is dedicated to innovating eyecare solutions to improve patient treatment, particularly through its OMNI® Surgical System for glaucoma and TearCare® System for dry eye disease, both aimed at enhancing patient care and addressing significant eye health challenges.
FAQ
What is the current stock price of Sight Sciences (SGHT)?
What is the market cap of Sight Sciences (SGHT)?
What does Sight Sciences, Inc. do?
What products are offered by Sight Sciences in the Surgical Glaucoma segment?
What is the TearCare System?
Where is Sight Sciences, Inc. headquartered?
What were the findings of the GEMINI Study?
How does Sight Sciences contribute to treating dry eye disease?
What financial segment drives Sight Sciences' revenue?
Who can I contact for investor relations at Sight Sciences?
Are there any recent clinical highlights for Sight Sciences?
What trademarks does Sight Sciences hold?
